Skip to main content

Table 4 a. Disaggregated results of QALYs and costs

From: Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China

 

QALYs

Comparator

PF

PP

AEs

Total

Brentuximab vedotin

3.56

1.38

-0.02

4.92

Chemotherapy

0.95

1.03

-0.03

1.95

Incremental

2.61

0.35

0.01

2.97

Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us